The results revealed that early CD8 T cell proliferation is associated with a positive clinical response to anti-PD-1 immunotherapy; thus, CD38 may be able to predict immunotherapy outcome in NSCLC [66]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.